{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:09:07Z","timestamp":1790611747046,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The primary objective of this study was to compare concomitant and hybrid therapy in the first line eradication treatment of <jats:italic>Helicobacter pylori<\/jats:italic> infection in Split-Dalmatia County, Croatia, in which clarithromycin resistance is above 20%. The secondary objective of the study was to determine and compare compliance and adverse events rate between these therapeutic protocols.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>In an open-label, randomised clinical trial 140 patients total with <jats:italic>H<\/jats:italic>. <jats:italic>pylori<\/jats:italic> infection were randomly assigned to either concomitant (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days) or hybrid (esomeprazole 40 mg and amoxicillin 1 g twice daily during 14 days with adding metronidazole 500 mg and clarithromycin 500 mg twice daily, in the last 7 days,) treatment group.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Eradication rates for concomitant group and hybrid therapy group were 84.1% (58\/69) and 83.1% (59\/71) respectively in the intention-to-treat analysis and 96.7% (58\/60) and 95.2% (59\/62) in per-protocol analysis. There was no significant difference between the groups (ITT analysis: <jats:italic>P<\/jats:italic> = 0.878; PP analysis: <jats:italic>P<\/jats:italic> = 0.675). Adverse events were more frequent in the concomitant group (33.3% vs 18.3%, <jats:italic>P<\/jats:italic> = 0.043). There was no difference among groups regarding compliance rate.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Hybrid therapy has similar eradication rate as concomitant therapy, with lower adverse events rate. In the era of increasing antibiotic resistance, eradication regime with less antibiotic\u2019s usage, as hybrid therapy, should be reasonable first line treatment choice for <jats:italic>H<\/jats:italic>. <jats:italic>pylori<\/jats:italic> infection.<\/jats:p>\n<jats:p>Clinical Trials, gov: NCT03572777.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0244500","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T19:18:43Z","timestamp":1609355923000},"page":"e0244500","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-2748","authenticated-orcid":true,"given":"Antonio","family":"Mestrovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josko","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Pavicic Ivelja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Kardum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Puljiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ante","family":"Tonkic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"pone.0244500.ref001","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrgastro.2013.96","article-title":"Helicobacter pylori research: historical insights and future directions","volume":"10","author":"KM Fock","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0244500.ref002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"M Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"pone.0244500.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report","volume":"66","author":"P Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"pone.0244500.ref004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"WD Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"pone.0244500.ref005","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis.","volume":"64","author":"on behalf of faculty members of Kyoto Global Consensus Conference","year":"2015","journal-title":"Gut"},{"key":"pone.0244500.ref006","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","article-title":"Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis","volume":"99","author":"AC Ford","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"pone.0244500.ref007","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","article-title":"Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis","volume":"150","author":"YC Lee","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0244500.ref008","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"A Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"pone.0244500.ref009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"I Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0244500.ref010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","article-title":"Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.","volume":"16","author":"PI Hsu","year":"2011","journal-title":"Helicobacter"},{"key":"pone.0244500.ref011","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3748\/wjg.v22.i19.4766","article-title":"Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis","volume":"22","author":"ZQ Song","year":"2016","journal-title":"World J Gastroenterol"},{"key":"pone.0244500.ref012","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.3748\/wjg.v21.i36.10435","article-title":"Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial","volume":"21","author":"KY Chen","year":"2015","journal-title":"World J Gastroenterol"},{"key":"pone.0244500.ref013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"CA Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0244500.ref014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1179\/1973947812Y.0000000001","article-title":"Time trends of primary antibiotic resistance of Helicobacter pylori isolates","volume":"24","author":"A Tonkic","year":"2012","journal-title":"Southern Croatia. J Chemother"},{"key":"pone.0244500.ref015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"DY Graham","year":"2010","journal-title":"Gut"},{"key":"pone.0244500.ref016","doi-asserted-by":"crossref","first-page":"e12466","DOI":"10.1111\/hel.12466","article-title":"Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton\u2010pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea","volume":"23","author":"JW Choe","year":"2018","journal-title":"Helicobacter"},{"key":"pone.0244500.ref017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4166\/kjg.2018.71.1.31","article-title":"Concomitant or sequential therapy as the first\u2010line therapy for eradication of Helicobacter pylori infection in Korea: a systematic review and meta\u2010analysis","volume":"71","author":"HJ Bae","year":"2018","journal-title":"Korean J Gastroenterol"},{"key":"pone.0244500.ref018","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/MEG.0000000000001517","article-title":"Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study","volume":"31","author":"C Kapizioni","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0244500.ref019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics","volume":"157","author":"CA Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0244500.ref020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejim.2016.04.011","article-title":"Randomized clinical trial comparing ten-day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area","volume":"32","author":"SD Georgopoulos","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"10","key":"pone.0244500.ref021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41395-018-0217-2","article-title":"Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection","volume":"113","author":"MJ Chen","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"pone.0244500.ref022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/hel.12180","article-title":"Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta\u2010analysis","volume":"20","author":"B Wang","year":"2015","journal-title":"Helicobacter"},{"key":"pone.0244500.ref023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/jpp.JPP_24_17","article-title":"Hybrid therapy versus sequential therapy for eradication of Helicobacter pylori: a randomized controlled trial","volume":"8","author":"S Ashokkumar","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"pone.0244500.ref024","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/jgh.12983","article-title":"Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial","volume":"30","author":"J Heo","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0244500.ref025","first-page":"205","article-title":"Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial","volume":"31","author":"SD Georgopoulos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"pone.0244500.ref026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.15171\/mejdd.2016.24","article-title":"A Comparison between Hybrid and Concomitant Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.","volume":"8","author":"S Alhooei","year":"2016","journal-title":"Middle East J Dig Dis"},{"key":"pone.0244500.ref027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2036.2003.01461.x","article-title":"High eradication rates of Helicobacter pylori with a new sequential treatment","volume":"17","author":"A Zullo","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0244500.ref028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hel.12017","article-title":"Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial","volume":"18","author":"H Sardarian","year":"2013","journal-title":"Helicobacter"},{"key":"pone.0244500.ref029","first-page":"48","article-title":"Treatment of Helicobacter pylori infection: A clinical practice update","author":"RM Zagari","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"pone.0244500.ref030","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/gutjnl-2015-310142","article-title":"Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial","volume":"65","author":"JM Liou","year":"2016","journal-title":"Gut"},{"issue":"1","key":"pone.0244500.ref031","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.gastro.2013.03.050","article-title":"Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance","volume":"145","author":"J Molina-Infante","year":"2013","journal-title":"Gastroenterology"},{"key":"pone.0244500.ref032","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/jmm.0.072322-0","article-title":"Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study","volume":"63","author":"V De Francesco","year":"2014","journal-title":"J Med Microbiol"},{"key":"pone.0244500.ref033","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study","volume":"37","author":"A Zullo","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"pone.0244500.ref034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000369898","article-title":"The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece.","volume":"90","author":"GP Karamanolis","year":"2014","journal-title":"Digestion"},{"key":"pone.0244500.ref035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ebiom.2018.08.028","article-title":"The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial.","volume":"35","author":"L Chen","year":"2018","journal-title":"EBioMedicine"},{"key":"pone.0244500.ref036","doi-asserted-by":"crossref","first-page":"e12590","DOI":"10.1111\/hel.12590","article-title":"The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults","volume":"24","author":"C He","year":"2019","journal-title":"Helicobacter"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T19:18:56Z","timestamp":1609355936000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244500"}},"subtitle":[],"editor":[{"given":"Lise Lotte","family":"Gluud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244500","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]}}}